Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct;30(10):783-92.
doi: 10.1007/s40266-013-0108-6.

Successes and failures for drugs in late-stage development for Alzheimer's disease

Camryn Berk  1 , Marwan N Sabbagh
Affiliations
Review

Successes and failures for drugs in late-stage development for Alzheimer's disease

Camryn Berk et al. Drugs Aging. 2013 Oct.

Erratum in

  • Drugs Aging. 2014 Jan;31(1):81

Abstract

To date, symptomatic medications prevail as the mainstay of treatment options for Alzheimer's disease (AD). There have been tremendous investments made to increase the numbers of drugs approved and the targets engaged, in an effort to alter the disease course or pathophysiology of AD. Unfortunately, almost all studies have not met expectations and no new drug (beyond medical foods) has been approved for the treatment of AD in the last decade. This review is a comparison of novel AD therapies in the late phases of clinical testing, including recent high-profile clinical failures, and agents in development with relatively unexplored mechanisms of action, with a focus on their potential as therapeutic agents and their proposed advantages over the treatments currently in use.

PubMed Disclaimer

References

    1. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119–22. - PubMed
    1. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991 Apr;41(4):479–86. - PubMed
    1. Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013 Jan 21;5(1):6. Epub ahead of print. - PMC - PubMed
    1. Downing N, Aminawung A, Shah N, et al. Regulatory Review of Novel Therapeutics- Comparison of Three Regulatory Agencies. New England Journal of Med. 2012;366:2284–2293. - PMC - PubMed
    1. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003 May 22;38(4):547–54. - PubMed

Publication types